Watch leading implanters discuss tricuspid leaflet repair therapy

Video Highlights

Uniqueness of tricuspid regurgitation
History of Edwards Lifesciences
PASCAL repair system in
tricuspid valve
PASCAL Ace implant
Why tricuspid therapy?

An innovative system designed to address the complexity of tricuspid repair

Effectively bridges the coaptation gap while optimising leaflet capture

Independent grasping for optimal placement while
respecting native anatomy

  • Atraumatic clasps with a single row of retention elements designed for fragile leaflets
  • Staged capture and capture optimization facilitate maximum leaflet insertion
Specifically designed to reduce stress on fragile leaflets

Central spacer effectively bridges the coaptation gap

  • Broad, contoured paddles increase coaptation area
  • Spacer reduces leaflet stress and increases open orifice area
Approach your procedure with confidence

Safely navigate your procedure within the
subvalvular apparatus

  • Implant elongation facilitates safe repositioning in dense tricuspid chordae
  • Independent catheters allow for predictable implant positioning
Click to get the PASCAL Repair System for TR Brochure

The PASCAL repair system showed promising results in First-in-Human experience1,2,*

In early compassionate use experience, the PASCAL repair system demonstrated high procedural success, significant clinical improvements, and sustainable TR reduction in patients with challenging tricuspid anatomy and severe TR. In addition, favorable right ventricular remodeling was observed at the 30-day follow-up.

Procedural Success


Grasping Used


Mortality at
30 days


Residual TR≤2+
at 6 months


*Site reported TR severity – no Echo Core Lab analyses

THE CLASP TR Early Feasibility Study3

30-day outcomes from the prospective, multicenter, single-arm study of the PASCAL repair system for patients with symptomatic TR


  • Multicenter, prospective, single-arm study in the United States
  • 34 patients underwent transcatheter tricuspid repair therapy with the PASCAL repair system
    • Mean age: 76 years
    • NYHA Class III/IV: 79%
    • TR severity ≥ severe (3+ grade): 97%
    • Atrial fibrillation/flutter: 88%


At 30 days:

  • PASCAL repair system shows a favourable safety profile and performed as intended in patients with symptomatic tricuspid regurgitation.
  • Despite 55% of patients having torrential TR at baseline, at 30 days 85% had TR reduction of at least one grade while 70% had TR reduction of at least two grades.
  • The major adverse event rate was low at 5.9%, with no mortality, stroke, myocardial infarction, or reintervention.
  • Patients experienced significant improvements in functional status, quality of life, and exercise capacity.
View Figures


  • In this early experience, the PASCAL repair system performed as intended, with substantial TR reduction, favourable safety results with a low MAE rate, no mortality or reintervention, and significant improvements in functional status, exercise capacity, and quality of life.
For a more detailed overview of the CLASP TR EFS, please download the clinical summary.

CLASP TR Early Feasibility Study Clinical Summary

Video Resources

Watch the PASCAL repair system procedural animation

Register for PASCAL repair system updates

Sign up now to receive event and news information from Edwards Lifesciences including:

  • Publications
  • Congress highlights
  • Webinar invites
  • Product announcements and updates
TMTT Portfolio

Learn more about Edwards' transcatheter mitral and tricuspid portfolio

Makeamark icon

Explore TMTT's portfolio of innovative therapies

Learn more
  1. Fam NP et al. Compassionate Use of the PASCAL Transcatheter Valve Repair System for Severe Tricuspid Regurgitation: A Multicenter, Observational, First-in-Human Experience. J Am Coll Cardiol. 2019;12(24).
  2. Lurz P et al. Six-month results of the PASCAL transcatheter valve repair system for severe tricuspid regurgitation: a multicentre, observational, first-in-human experience. PCR e-course 2020. 2020 June. Euro20A-POS487.
  3. Kodali S.,et al. Feasibility Study of the Transcatheter Valve Repair System for Severe Tricuspid Regurgitation JACC 2021;77(4):345-356.

For professional use

For professional use

For professional use. For a listing of indications, contraindications, precautions, warnings, and potential adverse events, please refer to the Instructions for Use (consult where applicable).

Edwards devices placed on the European market meeting the essential requirements referred to in Article 3 of the Medical Device Directive 93/42/EEC bear the CE marking of conformity.

Edwards, Edwards Lifesciences, the stylized E logo, Cardioband, PASCAL, PASCAL Ace, Valtech, and Valtech Cardio are trademarks or service marks of Edwards Lifesciences Corporation or its affiliates. All other trademarks are the property of their respective owners.

© 2020 Edwards Lifesciences Corporation. All rights reserved. PP—EU-0408 v3.0

Edwards Lifesciences • Route de l’Etraz 70, 1260 Nyon, Switzerland •

Please update your browserClose this window

Please update to a current version of your preferred browser, this site will perform effectively on the following:

Unable to update your browser?

If you are on a computer, that is maintained by an admin and you cannot install a new browser, ask your admin about it. If you can't change your browser because of compatibility issues, think about installing a second browser for browsing and keep this old one for compatibility